CXCR4 and infection: Our prediction on CRF02_AG isolates is consistent with previous observation [3], and thus shows that individuals infected with CRF02_AG are likely to benefit from coreceptor antagonists like maraviroc, though high CXCR4 usage has been observed in late infections involving CRF02_AG [59].